Accessibility Menu
Rocket One logo

Rocket One(NASDAQ) RKTO

Market Cap$17.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-98%
1 Year-41%
1 Month-15%
$0.68
-1.09%
-0.01Today
Rocket One last closing stock price
MetricPriceDate
Last closeUSD 0.682026-09-01
Rocket One stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8%USD 0.742026-08-25
1 month-15.07%USD 0.802026-07-31
3 month-68.22%USD 2.142026-06-03
Year to date-31.31%USD 0.992025-12-31
1 year-41.38%USD 1.162025-08-29
3 year-68.95%USD 2.192023-09-01
5 year-97.91%USD 32.502021-09-02
Since inception-99.68%USD 213.252019-02-15

Rocket One Financials at a Glance

Market Cap

$17.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.32M

EPS (TTM)

-$0.83

P/E Ratio

-0.83

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$0.68

Volume

174,843.187

Open

$0.68

Previous Close

$0.68

Daily Range

$0.68 - $0.72

52-Week Range

$0.49 - $2.45

Estimated Earnings Date

N/A

RKTO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rocket One

Hoth Therapeutics develops medicines for people with hard-to-treat diseases. Its products aim to help those with skin, cancer, and brain conditions. The company focuses on treatments that address needs not met by current drugs.

Lab Coats & Life Savers: What Hoth Sells

  • Skin Disorder Therapies: Topical treatments for rashes from cancer drugs; targets patients on specific cancer therapies. (0% revenue)
  • Cancer and Allergy Solutions: Drugs for rare cancers and severe allergic reactions; aimed at patients with mast-cell diseases. (0% revenue)
  • Brain and Nerve Disease Candidates: Experimental drugs for Alzheimer’s and other brain inflammation diseases. (0% revenue)
  • Inflammatory Disease Treatments: Products for bowel disease, acne, psoriasis, asthma, and allergies. (0% revenue)
  • Infection and COVID-19 Therapies: Medicines for lung infections and a peptide for COVID-19. (0% revenue)
  • BioLexa Platform: Early-stage eczema treatment using a patented drug delivery system. (0% revenue)

Growth Spurts & Science Sprints

  • Acquired patent applications from Med30, LLC in January 2025 for $1.25 million (cash and shares).
  • Entered research partnerships with Weill Cornell Medicine and licensing deals with seven universities since 2017.
  • Launched an equity sales program with H.C. Wainwright & Co. in 2025, raising $2.8 million by August 2025.
  • Expanded drug pipeline to cover dermatology, oncology, immunology, and neuroinflammation since 2017.

What Makes Hoth a Bit Different

Hoth operates with a small team but manages a broad drug pipeline. It partners with major research institutions to access new drug ideas. The company focuses on both topical and systemic treatments, using different delivery methods.

Five Things You Need to Know

  • No revenue reported for the six months ended June 30, 2025.
  • Net loss was $5.7 million in H1 2025, up 47% from H1 2024.
  • Cash and cash equivalents were $9.0 million as of June 30, 2025.
  • All funding comes from equity sales; no product sales to date.
  • R&D expenses rose 150% to $3.0 million in H1 2025 from H1 2024.

Bottom Line

Hoth remains a pre-revenue biotech focused on early-stage drug development. Its future depends on research progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6

CEO

Robbie Knie

Website

www.hoththerapeutics.com

Headquarters

Hoboken, NJ 07030, US

RKTO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-199.23%

Return on Capital

-180.48%

Return on Assets

-138.98%

Earnings Yield

-1.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.90M

Volume

174.84K

Avg. Volume

5.40M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$13.17M

EBITDA

-$13.32M

Operating Cash Flow

-$10.66M

Capital Expenditure

$7.00

Free Cash Flow

-$10.66M

Cash & ST Invst.

$7.89M

Total Debt

$0.00

Rocket One Performance Analysis

Rocket One annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Rocket One sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Rocket One annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -9.50-40.7%
20232023-12-31USD -2.38-75.0%
20242024-12-31USD -1.28-46.0%
20252025-12-31USD -0.90-29.7%
Rocket One sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-76.5%
Q42025-12-3143.3%
Q12026-03-31N/A
Q22026-06-30-11.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$17.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.85M

N/A

Employees

6

N/A

Net Income

-$3.83M

-74.3%

EBITDA

-$3.83M

-74.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.89M

-12.4%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.39%

N/A

Return on Invested Capital

-1.61%

N/A

Free Cash Flow

-$2.97M

-25.1%

Operating Cash Flow

-$2.97M

-25.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTOEntero Therapeutics, Inc.
$2.85-5.00%
DAREDare Bioscience, Inc.
$0.77+1.21%
PCSAProcessa Pharmaceuticals, Inc.
$2.05+0.00%
PULMPulmatrix, Inc.
$1.53+3.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About RKTO

What is the current price of Rocket One?

Rocket One is trading at $0.68 per share.

What is the 52-week range for Rocket One?

Over the past 52 weeks, Rocket One has traded between $0.49 and $2.45.

How much debt does Rocket One have?

As of the most recent reporting period, Rocket One reported total debt of $0.00.

How much cash does Rocket One have on hand?

Rocket One reported $7.89M in cash and cash equivalents in its most recent financial results.

What is Rocket One’s dividend yield?

Rocket One does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services